Hormonal
In obese and insulin-resistant individuals, adipose tissue exhibits a structural remodeling characterized by decreased capillary density, increased large vessel formation, reduced elastin, and increased Collagen V deposition around large vessels, which collectively inhibit angiogenesis and promote tissue stiffness.
This research highlights that obesity involves complex structural changes in fat tissue, specifically a shift toward stiffer tissue with fewer capillaries and more large vessels. While this paper does not prescribe a specific exercise or diet, it underscores that metabolic health is closely tied to tissue structure. Managing insulin sensitivity through lifestyle interventions may help mitigate these structural changes, though the paper focuses on describing the pathology rather than offering a treatment protocol.
The adipose tissue from obese/insulin-resistant subjects has fewer capillaries and more large vessels as compared with lean subjects. The ECM of adipose tissue may play an important role in regulating the expandability as well as angiogenesis of adipose tissue.
Why this rating
Strong human observational data combined with in vitro mechanistic validation, though limited by the small subgroup size (n=17) for histological analysis.
Source
Adipose Tissue Extracellular Matrix and Vascular Abnormalities in Obesity and Insulin Resistance
Michael Spencer et al. · The Journal of Clinical Endocrinology & Metabolism · 2011
DOI 10.1210/jc.2011-1567
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →